Overview

Genotype-guided Treatment in DLBCL

Status:
Not yet recruiting

Trial end date:
2026-06-01

Target enrollment:

Participant gender:

Summary

A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of genotype-guided targeted agents plus rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP-X) versus rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with diffuse large B-cell lymphoma

Phase:

Phase 3

Details

Lead Sponsor:

Ruijin Hospital

Treatments:

Cyclophosphamide
Decitabine
Doxorubicin
Lenalidomide
Prednisone
Rituximab
Vincristine